Clinical Trials · NCT05564039
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 282
- Start date
- Nov 2022
- Locations
- 38 sites, 5 countries
- Primary endpoint
- Change From Baseline in HbA1c